WhatPeptide

CJC-1295

A modified GHRH analog designed to prolong endogenous GH pulse support through albumin binding (DAC form). Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain.

Moderate evidence FDA Category 2 GH Secretagogue

Written by WhatPeptide Editorial Team · Last updated 2026-03-17

FDA Category 2 — compounding availability may be limited.

Half-life

About 5-8 days (DAC form)

Dosage range

1-2 mg weekly (DAC versions in compounding context)

Administration

Subcutaneous injection

Research level

Moderate

How CJC-1295 works

CJC-1295 acts at GHRH receptors in the pituitary to increase pulsatile GH release and downstream IGF-1 signaling. DAC conjugation extends circulation time compared with shorter GHRH analogs. Clinical data show endocrine effects, but long-term outcome and safety evidence is limited.

Also known as: CJC-1295 DAC, Drug affinity complex GHRH analog

Research relevance

GH Boost
Strong research relevance 90
Muscle Growth
Moderate relevance 75
Anti-Aging & Longevity
Moderate relevance 70
Recovery & Healing
Moderate relevance 60
Sleep & Relaxation
Moderate relevance 60
Fat Loss
Some relevance 45
Cognition & Focus
Some relevance 35
Hair & Skin
Some relevance 35
Injury Rehab
Some relevance 35
Sexual Health
Some relevance 30
Immune Support
Some relevance 20

Side effects & safety

Water retention Tingling Injection-site irritation Headache Elevated IGF-1 — theoretical concern for cancer promotion with prolonged use Possible insulin resistance with chronic use

Contraindications

Active cancer risk discussion required
Pregnancy
Uncontrolled diabetes

Consult a healthcare provider before use if any of these apply to you.

Key studies

FAQ

What is CJC-1295? +
A modified GHRH analog designed to prolong endogenous GH pulse support through albumin binding (DAC form). Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain. Its mechanism of action is supported by moderate clinical and preclinical evidence.
What is CJC-1295 researched for? +
CJC-1295 has the strongest research relevance for GH Boost, Muscle Growth, Anti-Aging & Longevity. Evidence is supported by moderate clinical and preclinical evidence.
What are the side effects of CJC-1295? +
Reported side effects include Water retention, Tingling, Injection-site irritation, Headache, Elevated IGF-1 — theoretical concern for cancer promotion with prolonged use, Possible insulin resistance with chronic use. Key contraindications: Active cancer risk discussion required; Pregnancy; Uncontrolled diabetes.
Is CJC-1295 FDA approved? +
CJC-1295 is classified as FDA Category 2, meaning compounding availability may be limited.
How is CJC-1295 administered? +
CJC-1295 is typically administered via subcutaneous route. Researched dosage range: 1-2 mg weekly (DAC versions in compounding context). Half-life: About 5-8 days (DAC form).

Explore similar peptides

CJC-1295 (No DAC)

Moderate evidence

GH Secretagogue

CJC-1295 without DAC (also called Modified GRF 1-29) is a GHRH analog with a shorter half-life than the DAC version, making it preferred for mimicking pulsatile physiological GH release when administered with a GHRP. It is widely used in research and wellness contexts for GH optimization.

MK-677

Moderate evidence

GH Secretagogue

An oral non-peptide ghrelin receptor agonist often discussed with GH peptides due to GH/IGF-1 stimulating effects. Placed on FDA Category 2 list (September 29, 2023) as 'Ibutamoren mesylate.'

Sermorelin

Strong evidence

GH Secretagogue

FDA-approved as GEREF for diagnosis and treatment of growth hormone deficiency in children (NDA 20-443, approved September 26, 1997). Voluntarily withdrawn from market June 2009 for commercial reasons — not for safety or efficacy concerns (Federal Register 78 FR 14095, March 4, 2013). Remains compoundable under Section 503A.

Tesamorelin

Strong evidence

GH Secretagogue

A stabilized GHRH analog approved for reduction of excess visceral fat in HIV-associated lipodystrophy.